Terms: = Gastric cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9
72 results:
1. State of the scientific evidence and recommendations for the management of older patients with gastric cancer.
Paredero-Pérez I; Jimenez-Fonseca P; Cano JM; Arrazubi V; Carmona-Bayonas A; Covela-Rúa M; Fernández-Montes A; Martín-Richard M; Gironés-Sarrió R
J Geriatr Oncol; 2024 Apr; 15(3):101657. PubMed ID: 37957106
[TBL] [Abstract] [Full Text] [Related]
2. Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms.
Riechelmann RP; Donadio MDS; Jesus VHF; de Carvalho NA; Santiago KM; Barros MJ; Lopes L; Oliveira Dos Santos G; Nirvana Formiga M; Carraro DM; Torrezan GT
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36947458
[TBL] [Abstract] [Full Text] [Related]
3. C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study.
Liu T; Zhang Q; Song C; Siyin ST; Chen S; Zhang Q; Song M; Cao L; Shi H
Int J Cancer; 2022 Jul; 151(2):297-307. PubMed ID: 35368093
[TBL] [Abstract] [Full Text] [Related]
4. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
[TBL] [Abstract] [Full Text] [Related]
5. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.
Van Cutsem E; Valderrama A; Bang YJ; Fuchs CS; Shitara K; Janjigian YY; Qin S; Larson TG; Shankaran V; Stein S; Norquist JM; Kher U; Shah S; Alsina M
ESMO Open; 2021 Aug; 6(4):100189. PubMed ID: 34371381
[TBL] [Abstract] [Full Text] [Related]
6. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Van Cutsem E; Amonkar M; Fuchs CS; Alsina M; Özgüroğlu M; Bang YJ; Chung HC; Muro K; Goekkurt E; Benson AB; Sun W; Wainberg ZA; Norquist JM; Chen X; Shih CS; Shitara K
Gastric Cancer; 2021 Nov; 24(6):1330-1340. PubMed ID: 34363528
[TBL] [Abstract] [Full Text] [Related]
7. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Lordick F; Al-Batran SE; Ganguli A; Morlock R; Sahin U; Türeci Ö
Gastric Cancer; 2021 May; 24(3):721-730. PubMed ID: 33755863
[TBL] [Abstract] [Full Text] [Related]
8. xpd Polymorphisms and Risk of Hepatocellular Carcinoma and gastric cancer: A Meta-Analysis.
Zhou Q; Fu Y; Wen L; Deng Y; Chen J; Liu K
Technol Cancer Res Treat; 2021; 20():1533033821990046. PubMed ID: 33517857
[TBL] [Abstract] [Full Text] [Related]
9. Exploration in the Mechanism of Kaempferol for the Treatment of gastric cancer Based on Network Pharmacology.
Yang L; Li H; Yang M; Zhang W; Li M; Xu Y; Li J; Kang J; Zhang J; Guo S
Biomed Res Int; 2020; 2020():5891016. PubMed ID: 33145355
[TBL] [Abstract] [Full Text] [Related]
10. Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
Fujitani K; Shitara K; Takashima A; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Hosaka H; Komatsu Y; Shimada K; Kawabata R; Ohdan H; Kodera Y; Nakamura M; Nakajima TE; Miyata Y; Moriwaki T; Kusumoto T; Nishikawa K; Ogata K; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2021 Mar; 24(2):467-476. PubMed ID: 33136231
[TBL] [Abstract] [Full Text] [Related]
11. ercc2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 Gene Polymorphisms Contribute to Subsceptibility of Colon, gastric, HCC, Lung And Prostate cancer.
Balkan E; Bilici M; Gundogdu B; Aksungur N; Kara A; Yasar E; Dogan H; Ozturk G
J BUON; 2020; 25(1):574-581. PubMed ID: 32277685
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive germline mutation analysis and clinical profile in a large cohort of Brazilian xeroderma pigmentosum patients.
Santiago KM; Castro LP; Neto JPD; de Nóbrega AF; Pinto CAL; Ashton-Prolla P; Pinto E Vairo F; de Medeiros PFV; Ribeiro EM; Ribeiro BFR; do Valle FF; Doriqui MJR; Leite CHB; Rocha RM; Moura LMS; Munford V; Galante PAF; Menck CFM; Rogatto SR; Achatz MI
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2392-2401. PubMed ID: 32239545
[TBL] [Abstract] [Full Text] [Related]
13. Genetic Polymorphisms in Inflammatory and Other Regulators in gastric cancer: Risks and Clinical Consequences.
Rudnicka K; Backert S; Chmiela M
Curr Top Microbiol Immunol; 2019; 421():53-76. PubMed ID: 31123885
[TBL] [Abstract] [Full Text] [Related]
14. Predictive Value of ERCC1, ercc2, and XRCC Expression for Patients with Locally Advanced or Metastatic gastric cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
[TBL] [Abstract] [Full Text] [Related]
15. Predictive Value of Two Polymorphisms of ercc2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in gastric cancer Patients: A Meta-Analysis.
Li M; Zhao Y; Zhao E; Wang K; Lu W; Yuan L
Dis Markers; 2018; 2018():3947626. PubMed ID: 30581498
[TBL] [Abstract] [Full Text] [Related]
16. DNA Repair Gene XRCC1 and xpd Polymorphisms and gastric cancer Risk: A Case-Control Study Outcome from Kashmir, India.
Nissar B; Kadla SA; Khan NS; Shah IA; Majid M; Afshan FU; Ganai BA
Anal Cell Pathol (Amst); 2018; 2018():3806514. PubMed ID: 30225185
[TBL] [Abstract] [Full Text] [Related]
17. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E; Zhang S; Cunningham D; Wotherspoon A; Soong R; Peckitt C; Valeri N; Fassan M; Rugge M; Okines A; Allum W; Stenning S; Nankivell M; Langley R; Tan P
Clin Cancer Res; 2017 Dec; 23(24):7543-7549. PubMed ID: 28972045
[No Abstract] [Full Text] [Related]
18. The intricate interplay between MSI and polymorphisms of DNA repair enzymes in gastric cancer H.pylori associated.
Silva-Fernandes IJL; Oliveira ES; Santos JC; Ribeiro ML; Ferrasi AC; Pardini MIMC; Burbano RMR; Rabenhorst SHB
Mutagenesis; 2017 Jul; 32(4):471-478. PubMed ID: 28927196
[TBL] [Abstract] [Full Text] [Related]
19. Association between the ercc2 Asp312Asn polymorphism and risk of cancer.
Xiao F; Pu J; Wen Q; Huang Q; Zhang Q; Huang B; Huang S; Lan A; Zhang Y; Li J; Zhao D; Shen J; Wu H; He Y; Li H; Yang X
Oncotarget; 2017 Jul; 8(29):48488-48506. PubMed ID: 28489582
[TBL] [Abstract] [Full Text] [Related]
20. Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
Meulendijks D; Rozeman EA; Cats A; Sikorska K; Joerger M; Deenen MJ; Beijnen JH; Schellens JHM
Pharmacogenomics J; 2017 Oct; 17(5):441-451. PubMed ID: 27995989
[TBL] [Abstract] [Full Text] [Related]
[Next]
